Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock
CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.06−0.38 (-15.40%)
Close on Nov 20, 2026Market cap $39.84MP/E –Yield –
Corbus Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Corbus Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2023 was -$36.10M. For fiscal 2025 it was -$64.50M. The highest annual figure on record is -$2.43M in fiscal 2014.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$64.50M | – |
| FY2024 | Dec 31, 2024 | -$41.79M | – |
| FY2023 | Dec 31, 2023 | -$36.10M | – |
| FY2022 | Dec 31, 2022 | -$37.56M | – |
| FY2021 | Dec 31, 2021 | -$48.24M | – |
| FY2020 | Dec 31, 2020 | -$100.17M | – |
| FY2019 | Dec 31, 2019 | -$48.46M | – |
| FY2018 | Dec 31, 2018 | -$32.37M | – |
| FY2017 | Dec 31, 2017 | -$28.50M | – |
| FY2016 | Dec 31, 2016 | -$13.92M | – |
| FY2015 | Dec 31, 2015 | -$4.74M | – |
| FY2014 | Dec 31, 2014 | -$2.43M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$29.63M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.42M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.01M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.80M | – |
| Q1 FY2023 | Mar 31, 2023 | -$15.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.25M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.63M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.76M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.17M | – |
| Q3 FY2020 | Sep 30, 2020 | -$27.31M | – |
| Q2 FY2020 | Jun 30, 2020 | -$26.62M | – |
| Q1 FY2020 | Mar 31, 2020 | -$28.06M | -373.9% |
| Q4 FY2019 | Dec 31, 2019 | -$23.85M | – |
| Q3 FY2019 | Sep 30, 2019 | -$18.28M | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.57M | – |
| Q1 FY2019 | Mar 31, 2019 | $10.24M | – |
| Q4 FY2018 | Dec 31, 2018 | -$14.31M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.95M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.23M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.87M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.69M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.38M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.76M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.68M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.57M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.12M | – |
See a number that looks wrong?